secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001171843-21-005577
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q2 revenue $38.1M (+24% YoY); raises FY revenue growth outlook to 11-14%
------------------------------------------------------------------------------

- Net income $6.5M ($0.45 diluted EPS) vs net loss $7.7M in Q2 2020.
- Adjusted net income $1.4M ($0.09 diluted EPS); adjusted EBITDA $6.1M.
- Joint Preservation and Restoration revenue up 79% to $11.9M; segment now 31% of total.
- Company raises FY 2021 revenue growth guidance to 11-14% from prior 10-13%.
- First surgical case with WristMotion Total Wrist implant; 510(k) clearance for reverse shoulder system.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184321005577/0001171843-21-005577-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184321005577/f8k_080521.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-005577

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer